Effects of phospholipase C inhibitors on Ca2+ channel stimulation and Ca2+ release from intracellular stores evoked by alpha 1A- and alpha 2A-adrenoceptors in rat portal vein myocytes

Biochem Biophys Res Commun. 1996 Jan 5;218(1):30-4. doi: 10.1006/bbrc.1996.0006.

Abstract

The ability of phospholipase C inhibitors to inhibit Ca2+ channel stimulation and Ca2+ release from intracellular stores evoked by norepinephrine in single rat portal vein myocytes was investigated in the aim of identifying the type of phospholipase C involved in the transduction pathways activated by alpha 1A- and alpha 2A-adrenoceptors. U73122 (an inhibitor of phosphatidylinositol-phospholipase C) inhibited in a concentration-dependent manner the release of Ca2+ from the intracellular stores induced by activation of alpha 1A-adrenoceptors and related to inositol phosphate production whereas U73343 was ineffective. Both compounds had no effect on the release of Ca2+ induced by caffeine. However, U73122 and U73343 inhibited the L-type Ca2+ channel. D609 (an inhibitor of phosphatidylcholine-phospholipase C) had no direct inhibitory effects on the L-type Ca2+ channel but it inhibited concentration dependently the alpha 2A-adrenoceptor-induced stimulation of Ca2+ channels, which had been shown to be independent of phosphatidylinositol hydrolysis. Therefore, these results suggest that alpha 2A-adrenoceptors activate a phosphatidylcholine-phospholipase C in vascular myocytes. However, D609 had other sites of action as it blocked norepinephrine- and caffeine-induced Ca2+ release from the intracellular stores.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bridged-Ring Compounds / pharmacology
  • Calcium / metabolism*
  • Calcium Channels / drug effects
  • Calcium Channels / physiology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology*
  • Estrenes / pharmacology*
  • In Vitro Techniques
  • Membrane Potentials / drug effects
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology*
  • Norbornanes
  • Norepinephrine / pharmacology
  • Patch-Clamp Techniques
  • Portal Vein / drug effects
  • Portal Vein / physiology*
  • Pyrrolidinones / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, alpha-1 / physiology*
  • Receptors, Adrenergic, alpha-2 / physiology*
  • Thiocarbamates
  • Thiones / pharmacology
  • Type C Phospholipases / antagonists & inhibitors*

Substances

  • Bridged-Ring Compounds
  • Calcium Channels
  • Enzyme Inhibitors
  • Estrenes
  • Norbornanes
  • Pyrrolidinones
  • Receptors, Adrenergic, alpha-1
  • Receptors, Adrenergic, alpha-2
  • Thiocarbamates
  • Thiones
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • U 73343
  • tricyclodecane-9-yl-xanthogenate
  • Type C Phospholipases
  • Calcium
  • Norepinephrine